,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,7,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
4,9,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
5,13,1,1,,133894,10205,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
6,15,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
7,19,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
8,21,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
9,23,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
10,25,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
11,29,1,1,,133894,10205,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
12,31,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
13,33,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
14,35,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
15,37,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
16,39,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
17,41,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
18,43,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
19,45,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
20,47,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
21,49,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
22,53,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
23,55,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
24,59,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
25,65,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
26,67,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
27,71,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
28,73,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
29,77,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
30,79,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
31,81,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
32,83,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
33,85,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
34,87,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
35,89,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
36,91,1,1,,133894,10205,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
37,93,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
38,95,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
39,97,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
40,99,1,1,,133894,10205,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
41,101,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
42,103,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
43,105,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
44,107,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
45,109,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
46,113,1,1,,133894,10205,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
47,115,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
48,119,1,1,,133894,10205,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
49,121,1,1,,133894,10205,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
50,123,1,1,,133894,10205,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
51,125,1,1,,133894,10205,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
52,129,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,Confirmatory,,
53,131,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
54,133,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
55,137,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
56,139,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
57,141,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
58,143,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
59,145,1,1,,133894,10205,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
60,155,1,1,,133894,10205,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
61,157,1,1,,133894,10205,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
62,161,1,1,,133894,10205,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
63,165,1,1,,133894,10205,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
64,167,1,1,,133894,10205,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
65,175,1,1,,133894,10205,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
66,179,1,1,,521949,10205,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
67,330,1,1,,133894,10205,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
68,875,1,2,,26747815,10205,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
69,875,1,2,,26753709,10205,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
70,880,2,1,,26747815,10205,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
71,880,2,1,,26747815,10205,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
72,880,2,1,,26753709,10205,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
73,880,2,1,,26753709,10205,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
74,881,2,2,,26747815,10205,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
75,881,2,2,,26753709,10205,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
76,884,1,2,,26747815,10205,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
77,884,1,2,,26753709,10205,Inconclusive,13435386.0,1576.0,31.6228,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
78,885,1,2,,26747815,10205,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
79,885,1,2,,26753709,10205,Inactive,13435386.0,1576.0,31.6228,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
80,887,1,2,,26747815,10205,Inconclusive,1832253.0,246.0,3.1623,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
81,887,1,2,,26753709,10205,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
82,889,1,3,,26747815,10205,Inconclusive,1730092.0,840.0,19.9526,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
83,889,1,3,,26753709,10205,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
84,892,1,2,,26747815,10205,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
85,892,1,2,,26753709,10205,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
86,893,1,2,,26747815,10205,Active,122921310.0,,12.5893,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
87,893,1,2,,26747815,10205,Active,122921311.0,,12.5893,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
88,893,1,2,,26753709,10205,Inconclusive,122921310.0,,39.8107,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
89,893,1,2,,26753709,10205,Inconclusive,122921311.0,,39.8107,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
90,894,2,1,,26747815,10205,Active,31542939.0,3248.0,25.1189,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
91,894,2,1,,26753709,10205,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
92,900,1,3,,26747815,10205,Inconclusive,15431328.0,834.0,12.5893,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
93,900,1,3,,26753709,10205,Inconclusive,15431328.0,834.0,31.6228,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
94,901,1,2,,26753709,10205,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
95,902,1,2,,26747815,10205,Active,120407068.0,7157.0,0.7943,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
96,902,1,2,,26753709,10205,Active,120407068.0,7157.0,10.0,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
97,910,1,2,,26747815,10205,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
98,923,1,2,,26747815,10205,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
99,923,1,2,,26753709,10205,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
100,924,1,2,,26747815,10205,Active,120407068.0,7157.0,3.9811,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
101,924,1,2,,26753709,10205,Active,120407068.0,7157.0,6.3096,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
102,927,1,3,,26747815,10205,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
103,930,1,2,,26747815,10205,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
104,940,1,2,,26612765,10205,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
105,995,1,2,,26747815,10205,Inconclusive,66932916.0,5594.0,10.0,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
106,995,1,2,,26753709,10205,Inconclusive,66932916.0,5594.0,19.9526,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
107,1030,2,1,,26747815,10205,Active,30582681.0,216.0,15.8489,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
108,1030,2,1,,26753709,10205,Inconclusive,30582681.0,216.0,39.8107,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
109,1379,1,2,,26747815,10205,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
110,1379,1,2,,26753709,10205,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
111,1422,1,1,,26612765,10205,Active,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
112,1452,1,1,,26747815,10205,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
113,1452,1,1,,26753709,10205,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
114,1454,1,1,,26747815,10205,Active,66932916.0,5594.0,5.6234,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
115,1454,1,1,,26753709,10205,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
116,1457,1,1,,26747815,10205,Inactive,44888968.0,83523.0,1.9953,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
117,1457,1,1,,26753709,10205,Inactive,44888968.0,83523.0,25.1189,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
118,1458,1,1,,26747815,10205,Inactive,10937869.0,6607.0,28.1838,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
119,1460,1,3,,26747815,10205,Active,92096784.0,4137.0,0.5623,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
120,1460,1,3,,26753709,10205,Active,92096784.0,4137.0,2.5119,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
121,1463,1,1,,26747815,10205,Active,,,0.8913,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
122,1463,1,1,,26753709,10205,Active,,,2.2387,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
123,1467,1,3,,26747815,10205,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
124,1467,1,3,,26753709,10205,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
125,1468,1,1,,26747815,10205,Active,92096784.0,4137.0,0.631,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
126,1468,1,1,,26753709,10205,Active,92096784.0,4137.0,3.1623,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
127,1469,1,1,,26747815,10205,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
128,1469,1,1,,26753709,10205,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
129,1471,2,1,,26747815,10205,Unspecified,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
130,1471,2,1,,26753709,10205,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
131,1476,2,1,,26747815,10205,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
132,1476,2,1,,26753709,10205,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
133,1477,1,1,,26753709,10205,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
134,1478,2,1,,26747815,10205,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
135,1478,2,1,,26753709,10205,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
136,1479,1,2,,26747815,10205,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
137,1479,1,2,,26753709,10205,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
138,1490,2,1,,26747815,10205,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
139,1490,2,1,,26753709,10205,Active,10954339.0,,35.4813,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
140,1519,1,3,,26747815,10205,Inconclusive,,,28.1838,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
141,1519,1,3,,26753709,10205,Inconclusive,,,14.1254,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
142,1724,1,1,,26747815,10205,Inactive,66932916.0,5594.0,,Potency,Confirmation Concentration-Response Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
143,1725,1,1,,26747815,10205,Active,66932916.0,5594.0,7.0795,Potency,Confirmation Concentration-Response Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
144,1728,1,1,,26747815,10205,Inconclusive,4506401.0,5894.0,25.1189,Potency,Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay: c-Raf Inhibition,Confirmatory,,
145,1730,1,1,,26747815,10205,Inconclusive,,,15.8489,Potency,Counterscreen Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
146,1732,1,1,,26747815,10205,Inconclusive,5579478.0,5604.0,12.5893,Potency,Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay: MEK Inhibition,Confirmatory,,
147,1766,1,1,,26747815,10205,Inconclusive,18860839.0,4221.0,31.6228,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
148,1766,1,1,,26747815,10205,Inconclusive,56550039.0,4297.0,31.6228,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
149,1766,1,1,,26753709,10205,Inactive,18860839.0,4221.0,31.6228,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
150,1766,1,1,,26753709,10205,Inactive,56550039.0,4297.0,31.6228,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
151,1768,1,1,,26747815,10205,Inconclusive,18860839.0,4221.0,11.2202,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
152,1768,1,1,,26747815,10205,Inconclusive,56550039.0,4297.0,11.2202,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
153,1768,1,1,,26753709,10205,Inconclusive,18860839.0,4221.0,10.0,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
154,1768,1,1,,26753709,10205,Inconclusive,56550039.0,4297.0,10.0,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
155,1865,1,1,,26747815,10205,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
156,1865,1,1,,26753709,10205,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
157,1948,1,1,,26747815,10205,Inactive,,,2.5119,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
158,1948,1,1,,26753709,10205,Inactive,,,5.0119,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
159,2101,1,1,,26747815,10205,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
160,2101,1,1,,26753709,10205,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
161,2107,1,1,,26747815,10205,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
162,2107,1,1,,26753709,10205,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
163,2112,1,1,,26747815,10205,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
164,2112,1,1,,26753709,10205,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
165,2147,1,1,,26747815,10205,Active,221046486.0,,8.9125,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
166,2147,1,1,,26753709,10205,Inconclusive,221046486.0,,6.3096,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
167,2240,1,1,,85789657,10205,Active,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
168,2241,1,1,,85789657,10205,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
169,2275,1,1,,85789657,10205,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
170,2313,1,1,,85789657,10205,Active,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
171,2322,1,1,,85789657,10205,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
172,2330,1,1,,85789657,10205,Active,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
173,2451,1,2,,26747815,10205,Inconclusive,122920737.0,,0.1119,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
174,2451,1,2,,26753709,10205,Inconclusive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
175,2472,1,2,,26747815,10205,Active,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
176,2472,1,2,,26753709,10205,Active,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
177,2517,2,1,,26747815,10205,Inconclusive,6980812.0,,28.1838,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
178,2517,2,1,,26753709,10205,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
179,2528,1,2,,26747815,10205,Inconclusive,4557365.0,641.0,31.6228,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
180,2528,1,2,,26753709,10205,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
181,2546,1,1,,26747815,10205,Inconclusive,188536040.0,19885.0,5.6234,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
182,2546,1,1,,26753709,10205,Active,188536040.0,19885.0,12.5893,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
183,2549,1,1,,26747815,10205,Inconclusive,282403581.0,,22.3872,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
184,2549,1,1,,26753709,10205,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
185,2551,1,1,,26747815,10205,Active,188536040.0,19885.0,2.5119,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
186,2551,1,1,,26753709,10205,Active,188536040.0,19885.0,14.1254,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
187,56357,6,2,,103222017,10205,Active,,,38.0,IC50,Concentration required for inhibition of human homologous Disulphide oxidoreductase (hGR),Confirmatory,10762041.0,
188,95926,5,2,,103222017,10205,Unspecified,,,,,In vitro antiparasitic activity against Leishmania donovani was tested by sigmoidal regression analysis; at 3 uM value is T/100,Other,11170645.0,
189,96103,7,1,,103222017,10205,Active,,,,,Compound dose toxic against macrophages of Leishmania donovani (100 % inhibition),Other,11170645.0,
190,103793,8,1,,103222017,10205,Unspecified,,,,,The second order rate constant of the pig heart LipDH (lipoamide dehydrogenase) catalyzed NADH oxidation.,Other,11170645.0,
191,103794,6,4,,103222017,10205,Unspecified,,,74.0,Km,The Michaelis-Menten constant for NADPH oxidation by pig heart LipDH (lipoamide dehydrogenase),Confirmatory,11170645.0,
192,103795,7,1,,103222017,10205,Unspecified,,,,,Vmax is the maximum velocity of the pig heart LipDH (lipoamide dehydrogenase) catalyzed NADH oxidation,Other,11170645.0,
193,103796,3,8,,103222017,10205,Unspecified,,,,,"Ratio of cytochrome c reduction and NADH oxidation by pig heart LipDH (lipoamide dehydrogenase) at 50 uM concentration, in cytochrome c assay",Other,11170645.0,
194,152094,6,2,,103222017,10205,Active,,,2.4,IC50,"In vitro antimalarial activity against human malaria parasite, P falciparum (Vietnam Smith strain)",Confirmatory,2033589.0,
195,208222,8,1,,103222017,10205,Active,,,1.5,ED50,In vitro antiparasitic activity against Trypanosoma brucei was tested by sigmoidal regression analysis,Confirmatory,11170645.0,
196,208238,5,2,,103222017,10205,Unspecified,,,,,In vitro antiparasitic activity against Trypanosoma cruzi was tested by sigmoidal regression analysis; at 10 uM value is T/100,Other,11170645.0,
197,208362,7,1,,103222017,10205,Active,,,,,Compound dose toxic against macrophages of Trypanosoma cruzi (100 % inhibition),Other,11170645.0,
198,212594,8,1,,103222017,10205,Unspecified,,,,,The second order rate constant of the TcLipDH (Trypanosoma cruzi lipoamide dehydrogenase) catalyzed NADH oxidation.,Other,11170645.0,
199,212595,6,2,,103222017,10205,Active,,,40.0,Km,The Michaelis-Menten constant for NADPH oxidation by TcLipDH (Trypanosoma cruzi lipoamide dehydrogenase),Confirmatory,11170645.0,
200,212596,7,1,,103222017,10205,Unspecified,,,,,Vmax is the maximum velocity of the TcLipDH (Trypanosoma cruzi lipoamide dehydrogenase) catalyzed NADH oxidation,Other,11170645.0,
201,212726,3,3,,103222017,10205,Unspecified,,,,,"Ratio of cytochrome c reduction and NADH oxidation by TcLipDH (Trypanosoma cruzi lipoamide dehydrogenase) at 50 uM concentration, in cytochrome c assay",Other,11170645.0,
202,212727,10,5,,103222017,10205,Active,136620.0,,28.0,IC50,"Inhibitory activity against Trypanosoma cruzi trypanothione disulfide reductase, assay in presence of 57 uM T(S)2.",Confirmatory,11170645.0,
203,212729,8,1,,103222017,10205,Unspecified,,,,,The second oder rate constant of the TcTR (Trypanosoma cruzi trypanothione reductase) catalyzed NADH oxidation.,Other,11170645.0,
204,212731,6,7,,103222017,10205,Active,136620.0,,15.0,Km,The Michaelis-Menten constant for NADPH oxidation by TcTR (Trypanosoma cruzi trypanothione reductase),Confirmatory,11170645.0,
205,212732,9,1,,103222017,10205,Unspecified,136620.0,,,,Vmax is the maximum velocity of the TcTR (Trypanosoma cruzi trypanothione reductase) catalyzed NADH oxidation.,Other,11170645.0,
206,212736,7,1,,103222017,10205,Unspecified,136620.0,,,,Rate of NADPH oxidation by TcTR in presence of 25 uM NQ was determined in comparison to intrinsic oxidase activity,Other,11170645.0,
207,214491,10,5,,103222017,10205,Active,136620.0,,28.0,IC50,Concentration required for inhibition of Trypanothione reductase (TcTR) from Trypanosoma cruzi in the presence of 50 uM TS2 as substrate,Confirmatory,10762041.0,
208,228426,8,2,,103222017,10205,Unspecified,,,,,Inhibition of topoisomerase I,Other,9873739.0,
209,356958,7,2,,103222017,10205,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus after 24 hrs by broth microdilution method,Other,12502328.0,
210,356959,5,1,,103222017,10205,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus after 48 hrs by broth microdilution method,Other,12502328.0,
211,356960,7,2,,103222017,10205,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus 8-8S after 24 hrs by broth microdilution method,Other,12502328.0,
212,356961,6,1,,103222017,10205,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus 8-8S after 48 hrs by broth microdilution method,Other,12502328.0,
213,356962,6,2,,103222017,10205,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis after 24 hrs by broth microdilution method,Other,12502328.0,
214,356963,6,1,,103222017,10205,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis after 48 hrs by broth microdilution method,Other,12502328.0,
215,356964,6,2,,103222017,10205,Unspecified,,,,,Antibacterial activity against vancomycin-resistant Enterococcus faecium F935 expressing VanA after 24 hrs by broth microdilution method,Other,12502328.0,
216,356965,6,1,,103222017,10205,Unspecified,,,,,Antibacterial activity against vancomycin-resistant Enterococcus faecium F935 expressing VanA after 48 hrs by broth microdilution method,Other,12502328.0,
217,356966,6,2,,103222017,10205,Unspecified,,,,,Antibacterial activity against vancomycin-resistant Enterococcus faecalis CKU-17 expressing VanB after 24 hrs by broth microdilution method,Other,12502328.0,
218,356967,6,1,,103222017,10205,Unspecified,,,,,Antibacterial activity against vancomycin-resistant Enterococcus faecalis CKU-17 expressing VanB after 48 hrs by broth microdilution method,Other,12502328.0,
219,357213,3,4,,103222017,10205,Unspecified,,,,,Ratio of MBC to MIC for Staphylococcus aureus,Other,12502328.0,
220,357214,3,4,,103222017,10205,Unspecified,,,,,Ratio of MBC to MIC for methicillin-resistant Staphylococcus aureus 8-8S,Other,12502328.0,
221,357215,3,4,,103222017,10205,Unspecified,,,,,Ratio of MBC to MIC for Enterococcus faecalis,Other,12502328.0,
222,357216,3,4,,103222017,10205,Unspecified,,,,,Ratio of MBC to MIC for vancomycin-resistant Enterococcus faecium F935 expressing VanA,Other,12502328.0,
223,357217,3,4,,103222017,10205,Unspecified,,,,,Ratio of MBC to MIC for vancomycin-resistant Enterococcus faecalis CKU-17 expressing VanB,Other,12502328.0,
224,379656,5,1,,103222017,10205,Unspecified,,,,,Larvicidal activity against Aedes aegypti assessed as drug level required to kill instar II larvae after 24 hrs,Other,10757739.0,
225,403267,8,1,,103222017,10205,Unspecified,,,,,Cytotoxicity against human KB cells,Other,15270571.0,
226,403268,5,1,,103222017,10205,Unspecified,,,,,Cytotoxicity against human Lu1 cells,Other,15270571.0,
227,403269,5,1,,103222017,10205,Unspecified,,,,,Cytotoxicity against human LNCAP cells,Other,15270571.0,
228,403270,5,1,,103222017,10205,Unspecified,,,,,Cytotoxicity against human HUVEC,Other,15270571.0,
229,403271,6,2,,103222017,10205,Unspecified,,,,,Antimicrobial activity against Micrococcus luteus after 18 hrs by zone-of-inhibition assay,Other,15270571.0,
230,403272,5,1,,103222017,10205,Unspecified,,,,,Antimicrobial activity against Micrococcus luteus assessed as 99.9 % growth inhibition after 18 hrs by zone-of-inhibition assay,Other,15270571.0,
231,403273,6,2,,103222017,10205,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus after 18 hrs by zone-of-inhibition assay,Other,15270571.0,
232,403274,5,1,,103222017,10205,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus assessed as 99.9 % growth inhibition after 18 hrs by zone-of-inhibition assay,Other,15270571.0,
233,403275,6,2,,103222017,10205,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis after 18 hrs by zone-of-inhibition assay,Other,15270571.0,
234,403276,5,1,,103222017,10205,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis assessed as 99.9 % growth inhibition after 18 hrs by zone-of-inhibition assay,Other,15270571.0,
235,403277,6,2,,103222017,10205,Unspecified,,,,,Antimicrobial activity against Mycobacterium avium after 18 hrs by zone-of-inhibition assay,Other,15270571.0,
236,403278,5,1,,103222017,10205,Unspecified,,,,,Antimicrobial activity against Mycobacterium avium assessed as 99.9 % growth inhibition after 18 hrs by zone-of-inhibition assay,Other,15270571.0,
237,403279,8,1,,103222017,10205,Unspecified,,,,,Antifungal activity against Candida albicans after 18 hrs by zone-of-inhibition assay,Other,15270571.0,
238,403280,8,1,,103222017,10205,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans after 18 hrs by zone-of-inhibition assay,Other,15270571.0,
239,403281,5,1,,103222017,10205,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans assessed as 99.9 % growth inhibition after 18 hrs by zone-of-inhibition assay,Other,15270571.0,
240,403282,6,2,,103222017,10205,Unspecified,,,,,Antifungal activity against Saccharomyces cerevisiae after 18 hrs by zone-of-inhibition assay,Other,15270571.0,
241,403283,5,1,,103222017,10205,Unspecified,,,,,Antifungal activity against Saccharomyces cerevisiae assessed as 99.9 % growth inhibition after 18 hrs by zone-of-inhibition assay,Other,15270571.0,
242,403284,6,2,,103222017,10205,Unspecified,,,,,Antifungal activity against Aspergillus niger after 18 hrs by zone-of-inhibition assay,Other,15270571.0,
243,403285,5,1,,103222017,10205,Unspecified,,,,,Antifungal activity against Aspergillus niger assessed as 99.9 % growth inhibition after 18 hrs by zone-of-inhibition assay,Other,15270571.0,
244,403286,3,3,,103222017,10205,Unspecified,,,,,Toxicity in human KB cell xenografted mouse assessed as body weight loss at 5 mg/kg,Other,15270571.0,
245,403287,3,3,,103222017,10205,Unspecified,,,,,Toxicity in human LNCaP cell xenografted mouse assessed as body weight loss at 5 mg/kg,Other,15270571.0,
246,403288,3,3,,103222017,10205,Unspecified,,,,,Toxicity in human LU1 cell xenografted mouse assessed as body weight loss at 5 mg/kg,Other,15270571.0,
247,403298,5,1,,103222017,10205,Unspecified,,,,,Antimicrobial activity against Candida albicans assessed as 99.9 % growth inhibition after 18 hrs by zone-of-inhibition assay,Other,15270571.0,
248,409958,3,9,,103222017,10205,Inactive,124028637.0,281293.0,,,Inhibition of bovine brain MAOA,Other,18834112.0,
249,434959,1,1,,85789657,10205,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
250,479263,8,1,,103222017,10205,Unspecified,,,,,Larvicidal activity against Aedes aegypti fourth instar larvae after 24 hrs,Other,20347303.0,
251,479265,3,3,,103222017,10205,Unspecified,,,,,Larvicidal activity against Aedes aegypti fourth instar larvae at 6.5 ug/ml after 24 hrs,Other,20347303.0,
252,485281,1,1,,26747815,10205,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
253,485290,1,1,,26747815,10205,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
254,485290,1,1,,26753709,10205,Inactive,20150581.0,,39.8107,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
255,492425,9,2,,103222017,10205,Active,,,0.27,IC50,Antimalarial activity against Plasmodium falciparum,Confirmatory,19299148.0,
256,493444,2,9,,103222017,10205,Unspecified,92090612.0,9020.0,,,Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells at 50 uM after 60 mins by radiometric protein kinase assay,Other,20580552.0,
257,493445,7,5,,103222017,10205,Unspecified,92090612.0,9020.0,100.0,IC50,Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells after 60 mins by radiometric protein kinase assay,Confirmatory,20580552.0,
258,504327,1,1,,26747815,10205,Inconclusive,153791535.0,2648.0,39.8107,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
259,504327,1,1,,26753709,10205,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
260,504332,1,1,,26747815,10205,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
261,504845,1,1,,26753709,10205,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
262,504847,1,1,,26747815,10205,Active,63054845.0,7421.0,0.8913,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
263,504847,1,1,,26753709,10205,Active,63054845.0,7421.0,7.9433,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
264,504865,1,1,,26747815,10205,Active,118600387.0,7398.0,17.7828,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
265,504865,1,1,,26753709,10205,Inconclusive,118600387.0,7398.0,50.1187,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
266,588379,1,2,,26753709,10205,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
267,588579,1,1,,26747815,10205,Active,7705344.0,51426.0,10.0,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
268,588579,1,1,,26753709,10205,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
269,602332,1,1,,26747815,10205,Inactive,168984549.0,,2.5119,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
270,602332,1,1,,26753709,10205,Inactive,168984549.0,,7.9433,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
271,624156,1,1,,85789657,10205,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
272,629592,3,3,,103222017,10205,Active,,,0.8,EC50,Cytotoxicity against human INA-6 cells assessed as viable fractions using annexin V-FITC/propidium iodide staining by flow cytometry,Confirmatory,22019229.0,
273,629593,3,2,,103222017,10205,Active,,,0.8,EC50,Cytotoxicity against human PBMC cells assessed as viable fractions using annexin V-FITC/propidium iodide staining by flow cytometry,Confirmatory,22019229.0,
274,657258,1,3,,103222017,10205,Unspecified,,,,,"Partition coefficient, log P pf the compound",Other,22483392.0,
275,657259,1,8,,103222017,10205,Active,62906901.0,5970.0,,,Inhibition of NFkappaB p65 subunit expression in human MDA-MB-231 cells at 1.5 uM after 48 hrs by Western blot analysis,Other,22483392.0,
276,657260,2,2,,103222017,10205,Active,,,2.5,IC50,Antiproliferative activity against ER-negative human MDA-MB-468 cells after 48 hrs by MTT assay,Confirmatory,22483392.0,
277,657261,2,2,,103222017,10205,Active,,,5.5,IC50,Antiproliferative activity against ER-positive human MCF7 cells after 24 hrs by MTT assay,Confirmatory,22483392.0,
278,657262,2,2,,103222017,10205,Active,,,3.5,IC50,Antiproliferative activity against ER-negative human MDA-MB-231 cells after 24 hrs by MTT assay,Confirmatory,22483392.0,
279,657867,1,3,,103222017,10205,Unspecified,,,,,Ratio of EC50 for human ACHN cells to EC50 for human ACHN cells in presence of 40 ng/ml TRAIL,Other,22313254.0,
280,660831,2,2,,103222017,10205,Active,,,3.7,EC50,Cytotoxicity against human ACHN cells assessed as cell death after 20 to 24 hrs by XTT assay,Confirmatory,22313254.0,
281,660832,2,2,,103222017,10205,Active,,,7.3,EC50,Cytotoxicity against human ACHN cells assessed as cell death after 20 to 24 hrs by XTT assay in presence of 40 ng/ml TRAIL,Confirmatory,22313254.0,
282,669208,1,3,,103222017,10205,Unspecified,,,,,Induction of apoptosis in Her2-overexpressing human BT474 cells assessed as increase in BaK protein level after 24 hrs by Western blot analysis,Other,22512718.0,
283,669209,1,3,,103222017,10205,Unspecified,,,,,Induction of apoptosis in Her2-overexpressing human BT474 cells assessed as increase in Bax protein level after 24 hrs by Western blot analysis,Other,22512718.0,
284,669210,1,3,,103222017,10205,Unspecified,,,,,Induction of apoptosis in Her2-overexpressing human SKBR3 cells assessed as increase in caspase activity after 6 hrs by fluorescence analysis relative to control,Other,22512718.0,
285,669211,1,3,,103222017,10205,Unspecified,,,,,Induction of apoptosis in Her2-overexpressing human BT474 cells assessed as increase in caspase activity at 10 uM after 6 hrs by fluorescence analysis relative to control,Other,22512718.0,
286,669212,1,3,,103222017,10205,Unspecified,,,,,Induction of apoptosis in Her2-overexpressing human SKBR3 cells assessed as increase in caspase activity after 6 hrs by fluorescence analysis,Other,22512718.0,
287,669213,1,3,,103222017,10205,Unspecified,,,,,Induction of apoptosis in Her2-overexpressing human BT474 cells assessed as increase in caspase activity after 6 hrs by fluorescence analysis,Other,22512718.0,
288,669214,1,3,,103222017,10205,Inactive,,,,,Induction of apoptosis in Her2-overexpressing human BT474 cells assessed as accumulation at subG1 phase by propidium iodide staining-based flow cytometric analysis,Other,22512718.0,
289,669215,1,3,,103222017,10205,Unspecified,,,,,Induction of cell cycle arrest in Her2-overexpressing human SKBR3 cells assessed as increase in DNA accumulation at subG1 phase at 10 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 11%),Other,22512718.0,
290,669216,1,3,,103222017,10205,Unspecified,,,,,Induction of cell cycle arrest in Her2-overexpressing human SKBR3 cells assessed as increase in DNA accumulation at subG1 phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 11%),Other,22512718.0,
291,669217,1,3,,103222017,10205,Unspecified,,,,,Induction of cell cycle arrest in Her2-overexpressing human SKBR3 cells assessed as increase in DNA accumulation at subG1 phase at 2.5 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 11%),Other,22512718.0,
292,669218,1,3,,103222017,10205,Unspecified,,,,,Induction of cell cycle arrest in Her2-overexpressing human SKBR3 cells assessed as increase in DNA accumulation at subG1 phase after 24 hrs by propidium iodide staining-based flow cytometric analysis,Other,22512718.0,
293,669219,1,3,,103222017,10205,Unspecified,,,,,Anticlonogenic activity in Her2-overexpressing human SKBR3 cells assessed as inhibition of colony formation at 1 uM after 6 hrs followed by washout measured after 16 days by crystal violet staining,Other,22512718.0,
294,669220,1,3,,103222017,10205,Unspecified,,,,,Anticlonogenic activity in Her2-overexpressing human BT474 cells assessed as inhibition of colony formation at 1 uM after 6 hrs followed by washout measured after 16 days by crystal violet staining,Other,22512718.0,
295,669221,2,3,,103222017,10205,Active,,,0.8,IC50,Cytotoxicity against Her2-overexpressing human BT474 cells after 72 hrs by MTT assay,Confirmatory,22512718.0,
296,669222,2,3,,103222017,10205,Active,,,1.8,IC50,Cytotoxicity against Her2-overexpressing human SKBR3 cells after 72 hrs by MTT assay,Confirmatory,22512718.0,
297,669223,2,3,,103222017,10205,Active,,,1.8,IC50,Cytotoxicity against Her2-overexpressing human BT474 cells after 24 hrs by MTT assay,Confirmatory,22512718.0,
298,669224,2,3,,103222017,10205,Active,,,3.2,IC50,Cytotoxicity against Her2-overexpressing human SKBR3 cells after 24 hrs by MTT assay,Confirmatory,22512718.0,
299,669225,1,4,,103222017,10205,Unspecified,,,,,Antitumor activity against human MDA-MB-231 cells xenografted in nude mouse assessed as decrease in tumor volume,Other,22512718.0,
300,669226,1,3,,103222017,10205,Unspecified,,,,,Ratio of IC50 for Her2-overexpressing human BT474 cells after 24 hrs to IC50 for Her2-overexpressing human BT474 cells after 72 hrs,Other,22512718.0,
301,669227,1,3,,103222017,10205,Unspecified,,,,,Cytotoxicity against Her2-overexpressing human SKBR3 cells after 24 to 72 hrs by MTT assay,Other,22512718.0,
302,669228,1,3,,103222017,10205,Unspecified,,,,,Cytotoxicity against Her2-overexpressing human BT474 cells after 24 to 72 hrs by MTT assay,Other,22512718.0,
303,669229,1,3,,103222017,10205,Unspecified,,,,,Anticlonogenic activity in Her2-overexpressing human BT474 cells assessed as inhibition of colony formation after 6 hrs followed by washout measured after 16 days by crystal violet staining,Other,22512718.0,
304,669230,1,3,,103222017,10205,Unspecified,,,,,Anticlonogenic activity in Her2-overexpressing human SKBR3 cells assessed as inhibition of colony formation after 6 hrs followed by washout measured after 16 days by crystal violet staining,Other,22512718.0,
305,670008,1,3,,103222017,10205,Active,,,,,Induction of apoptosis in Her2-overexpressing human SKBR3 cells assessed as decrease in Bcl-2 protein level after 24 hrs by Western blot analysis,Other,22512718.0,
306,670009,1,3,,103222017,10205,Active,,,,,Induction of apoptosis in Her2-overexpressing human BT474 cells assessed as decrease in Bcl-2 protein level after 24 hrs by Western blot analysis,Other,22512718.0,
307,670010,1,3,,103222017,10205,Unspecified,,,,,Induction of apoptosis in Her2-overexpressing human SKBR3 cells assessed as increase in BaK protein level after 24 hrs by Western blot analysis,Other,22512718.0,
308,670011,1,3,,103222017,10205,Unspecified,,,,,Induction of apoptosis in Her2-overexpressing human SKBR3 cells assessed as increase in Bax protein level after 24 hrs by Western blot analysis,Other,22512718.0,
309,686978,1,1,,26747815,10205,Active,79154014.0,55775.0,1.1582,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
310,686978,1,1,,26753709,10205,Active,79154014.0,55775.0,2.6609,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
311,686979,1,1,,26747815,10205,Active,79154014.0,55775.0,1.1582,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
312,686979,1,1,,26753709,10205,Active,79154014.0,55775.0,2.6609,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
313,696882,1,3,,103222017,10205,Active,,,,,Stimulation of ceramide formation in human erythrocytes at 2 uM after 48 hrs by FITC-labeled anticeramide antibody method,Other,23110447.0,
314,696883,1,3,,103222017,10205,Inactive,,,,,Induction of eryptosis in human erythrocytes assessed as cell membrane scrambling at 1 uM after 48 hrs by annexin V staining-based FACS analysis in nominal absence of extracellular Ca2+,Other,23110447.0,
315,696884,1,3,,103222017,10205,Active,,,,,Induction of eryptosis in human erythrocytes assessed as cell membrane scrambling at 1 uM after 48 hrs by annexin V staining-based FACS analysis in presence of extracellular Ca2+,Other,23110447.0,
316,696885,1,3,,103222017,10205,Active,,,,,Hemolysis in human erythrocytes assessed as release of hemoglobin at 1 uM after 48 hrs by spectrophotometry,Other,23110447.0,
317,696886,1,3,,103222017,10205,Active,,,,,Induction of eryptosis in human erythrocytes assessed as phosphatidylserine exposure up to 2 uM after 48 hrs by annexin V staining-based FACS analysis,Other,23110447.0,
318,696887,1,3,,103222017,10205,Active,,,,,Induction of eryptosis in human erythrocytes assessed as phosphatidylserine exposure at 1 uM after 48 hrs by annexin V staining-based FACS analysis,Other,23110447.0,
319,696888,1,3,,103222017,10205,Active,,,,,Induction of eryptosis in human erythrocytes assessed as reduction in cell volume measuring forward scatter up to 2 uM after 48 hrs by FACS analysis,Other,23110447.0,
320,696889,1,3,,103222017,10205,Active,,,,,Hemolysis in human erythrocytes assessed as release of hemoglobin up to 2 uM after 48 hrs by spectrophotometry,Other,23110447.0,
321,696890,1,3,,103222017,10205,Active,,,,,Induction of eryptosis in human erythrocytes assessed as increase in cytosolic Ca2+ at 0.5 uM after 48 hrs by Fluo-3/AM-based FACS analysis,Other,23110447.0,
322,696891,1,3,,103222017,10205,Active,,,,,Induction of eryptosis in human erythrocytes assessed as increase in cytosolic Ca2+ up to 2 uM after 48 hrs by Fluo-3/AM-based FACS analysis,Other,23110447.0,
323,696892,1,3,,103222017,10205,Active,,,,,Induction of eryptosis in human erythrocytes assessed as reduction in cell volume measuring forward scatter at 1.5 uM after 48 hrs by FACS analysis,Other,23110447.0,
324,697852,1,7,,103222017,10205,Unspecified,14916521.0,,,,Inhibition of electric eel AChE at 2 mg/ml by Ellman's method,Other,23062825.0,
325,697853,1,7,,103222017,10205,Unspecified,21362409.0,100033901.0,,,Inhibition of horse BChE at 2 mg/ml by Ellman's method,Other,23062825.0,
326,720532,1,1,,26747815,10205,Active,420597.0,,3.5481,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
327,720532,1,1,,26753709,10205,Active,420597.0,,3.9811,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
328,720533,1,1,,26747815,10205,Active,,,6.3096,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
329,720533,1,1,,26753709,10205,Active,,,3.1623,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
330,720579,2,1,,26747815,10205,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
331,720580,1,1,,26747815,10205,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
332,751137,1,1,,103222017,10205,Active,,,,,Antiinflammatory activity in C57-B16/J mouse chronic DSS-induced ulcerative colitis model assessed as restoration of colon size at 6 to 10 mg/kg administered for total of 3 weeks for alternative weeks with water measured after 63 days,Other,23742275.0,
333,751138,1,1,,103222017,10205,Active,,,,,Antiinflammatory activity in C57-B16/J mouse DSS-induced ulcerative colitis model assessed as reduction in monocyte aggregation at 10 mg/kg by hematoxylin-eosin staining-based microscopic analysis,Other,23742275.0,
334,751139,1,1,,103222017,10205,Active,,,,,Antiinflammatory activity in C57-B16/J mouse DSS-induced ulcerative colitis model assessed as restoration of submucosa at 10 mg/kg by hematoxylin-eosin staining-based microscopic analysis,Other,23742275.0,
335,751140,1,1,,103222017,10205,Active,,,,,Antiinflammatory activity in C57-B16/J mouse DSS-induced ulcerative colitis model assessed as restoration of crypts at 10 mg/kg by hematoxylin-eosin staining-based microscopic analysis,Other,23742275.0,
336,751141,1,1,,103222017,10205,Active,,,,,Antiinflammatory activity in C57-B16/J mouse DSS-induced ulcerative colitis model assessed as restoration of goblet cells at 10 mg/kg by hematoxylin-eosin staining-based microscopic analysis,Other,23742275.0,
337,751142,1,1,,103222017,10205,Active,,,,,Antiinflammatory activity in C57-B16/J mouse chronic DSS-induced ulcerative colitis model assessed as suppression of clinical symptoms at 8 to 10 mg/kg administered for total of 3 weeks for alternative weeks with water measured after 63 days,Other,23742275.0,
338,751143,1,2,,103222017,10205,Active,,,,,Antiinflammatory activity in C57-B16/J mouse chronic DSS-induced ulcerative colitis model assessed as decrease in serum IL-17 level at 10 mg/kg administered for total of 3 weeks for alternative weeks with water measured after 63 days by ELISA relative to DSS-treated control,Other,23742275.0,
339,751144,1,2,,103222017,10205,Inactive,,,,,Antiinflammatory activity in C57-B16/J mouse chronic DSS-induced ulcerative colitis model assessed as decrease in serum IL-17 level at 8 mg/kg administered for total of 3 weeks for alternative weeks with water measured after 63 days by ELISA relative to DSS-treated control,Other,23742275.0,
340,751145,1,2,,103222017,10205,Active,,,,,Antiinflammatory activity in C57-B16/J mouse chronic DSS-induced ulcerative colitis model assessed as decrease in serum IFNgamma level at 10 mg/kg administered for total of 3 weeks for alternative weeks with water measured after 63 days by ELISA relative to DSS-treated control,Other,23742275.0,
341,751146,1,2,,103222017,10205,Active,,,,,Antiinflammatory activity in C57-B16/J mouse chronic DSS-induced ulcerative colitis model assessed as decrease in serum TNFalpha level at 10 mg/kg administered for total of 3 weeks for alternative weeks with water measured after 63 days by ELISA relative to DSS-treated control,Other,23742275.0,
342,751147,1,1,,103222017,10205,Unspecified,,,,,Antiinflammatory activity in C57-B16/J mouse DSS-induced ulcerative colitis model assessed as reduction of inflammatory CD14+/CD16+ level in peripheral blood at 8 to 10 mg/kg by flow cytometric analysis relative to DSS-treated control,Other,23742275.0,
343,751148,1,1,,103222017,10205,Unspecified,,,,,Toxicity in C57-B16/J mouse DSS-induced ulcerative colitis model assessed as circulating CD14+/CD16- level at 6 to 10 mg/kg by flow cytometric analysis relative to DSS-treated control,Other,23742275.0,
344,751149,1,1,,103222017,10205,Unspecified,,,,,Antiinflammatory activity in C57-B16/J mouse DSS-induced ulcerative colitis model assessed as reduction of inflammatory CD14+/CD16+ level in peripheral blood at 6 to 10 mg/kg by flow cytometric analysis relative to DSS-treated control,Other,23742275.0,
345,751150,1,1,,103222017,10205,Unspecified,,,,,Oral bioavailability in rat,Other,23742275.0,
346,751151,1,1,,103222017,10205,Inactive,,,,,Antiinflammatory activity in C57-B16/J mouse acute DSS-induced ulcerative colitis model assessed as reversal of body weight loss at 6 to 10 mg/kg administered on day 6 measured up to day 12,Other,23742275.0,
347,751152,1,1,,103222017,10205,Active,,,,,Antiinflammatory activity in C57-B16/J mouse acute DSS-induced ulcerative colitis model assessed as suppression of clinical symptoms at 8 to 10 mg/kg administered on day 6 measured up to day 12,Other,23742275.0,
348,763573,1,5,,103222017,10205,Unspecified,48429227.0,6774.0,,,Binding affinity to STAT3 SH2 domain (unknown origin) using 5-FAM-SpYLPQTV as probe assessed as inhibition of protein dimerization at 500 uM after 60 mins by fluorescence polarization assay relative to control,Other,23791367.0,
349,763578,1,1,,103222017,10205,Active,,,4.19,IC50,Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay,Confirmatory,23791367.0,
350,763579,1,1,,103222017,10205,Active,,,21.24,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay,Confirmatory,23791367.0,
351,763580,1,1,,103222017,10205,Active,,,5.23,IC50,Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay,Confirmatory,23791367.0,
352,1062001,1,4,,103222017,10205,Active,2811086.0,1956.0,,,Inhibition of EGFR autophosphorylation at Y1068 in human MCF7 cells expressing HER2delta16 at 10 uM after 2 hrs by Western blotting,Other,24355130.0,
353,1062002,1,4,,103222017,10205,Active,2811086.0,1956.0,,,Inhibition of EGFR autophosphorylation at Y1068 in human MCF7 cells expressing HER2 at 10 uM after 2 hrs by Western blotting,Other,24355130.0,
354,1062003,1,4,,103222017,10205,Active,2811086.0,1956.0,,,Inhibition of EGFR autophosphorylation at Y1068 in human MCF7 cells expressing pcDNA3 at 10 uM after 2 hrs by Western blotting,Other,24355130.0,
355,1062004,1,2,,103222017,10205,Active,,,,,Inhibition of HER2 delta16 mutant autophosphorylation at Y1248 in human MCF7 cells at 10 uM after 2 hrs by Western blotting,Other,24355130.0,
356,1062005,1,4,,103222017,10205,Active,119533.0,2064.0,,,Inhibition of HER2 autophosphorylation at Y1248 in human MCF7 cells at 10 uM after 2 hrs by Western blotting,Other,24355130.0,
357,1062006,1,4,,103222017,10205,Active,119533.0,2064.0,,,Inhibition of HER2 autophosphorylation at Y1248 in human MCF7 cells expressing pcDNA3 at 10 uM after 2 hrs by Western blotting,Other,24355130.0,
358,1062007,2,3,,103222017,10205,Active,119533.0,2064.0,30.8,IC50,Inhibition of HER2 (unknown origin) by ADP-Glo assay,Confirmatory,24355130.0,
359,1062008,1,2,,103222017,10205,Active,,,5.1,IC50,Cytotoxicity against human MCF7 cells expressing HER2delta16 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay,Confirmatory,24355130.0,
360,1062009,1,2,,103222017,10205,Active,,,2.84,IC50,Cytotoxicity against human MCF7 cells expressing HER2 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay,Confirmatory,24355130.0,
361,1062010,1,2,,103222017,10205,Active,,,3.35,IC50,Cytotoxicity against human MCF7 cells expressing pcDNA3 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay,Confirmatory,24355130.0,
362,1062011,1,2,,103222017,10205,Unspecified,,,,,Cytotoxicity against human MCF7 cells expressing pcDNA3 assessed as reduction of cell viability at 10 uM after 48 hrs CellTiter-Glo assay,Other,24355130.0,
363,1062012,1,2,,103222017,10205,Unspecified,,,,,Cytotoxicity against human MCF7 cells expressing HER2delta16 assessed as reduction of cell viability at 10 uM after 48 hrs CellTiter-Glo assay,Other,24355130.0,
364,1062013,1,2,,103222017,10205,Unspecified,,,,,Cytotoxicity against human MCF7 cells expressing HER2 assessed as reduction of cell viability at 10 uM after 48 hrs CellTiter-Glo assay,Other,24355130.0,
365,1079952,1,2,,103222017,10205,Unspecified,,,,,Antifeedant activity against prestarved healthy third-instar larval stage of Achaea janata assessed as area of leaf consumed after 6 hr by conventional no-choice leaf-disk bioassay,Other,,
366,1079953,1,2,,103222017,10205,Unspecified,,,,,Antifeedant activity against prestarved healthy third-instar larval stage of Spodoptera litura assessed as area of leaf consumed after 6 hr by conventional no-choice leaf-disk bioassay,Other,,
367,1079958,1,1,,103222017,10205,Unspecified,,,,,Protection of intact cabbage plants from Trichoplusia ni (cabbage looper) measured as reduction in weight of larvae by lopper in green house for 10 days (Rvb = 33.8 mg),Other,23731643.0,
368,1079959,1,1,,103222017,10205,Unspecified,,,,,Protection of intact cabbage plants from Trichoplusia ni (cabbage looper) measured as leaf area consumed by lopper in green house for 10 days (Rvb = 8.5 cm'2),Other,23731643.0,
369,1079960,1,1,,103222017,10205,Unspecified,,,,,Toxicity against Trichoplusia ni (cabbage looper) third-instar larvae stage assessed as mortality at 10 ug/ml for 24 hr by topical application,Other,23731643.0,
370,1079961,1,1,,103222017,10205,Unspecified,,,,,Antifeedant activity against Trichoplusia ni (cabbage looper) third-instar larvae stage assessed as concentrations causing 50% feeding deterrence by feeding deterrent bioassay,Other,23731643.0,
371,1079962,1,1,,103222017,10205,Unspecified,,,,,Antifeedant activity against Trichoplusia ni (cabbage looper) third-instar larvae stage assessed as feeding deterrence index at 50 microg/cm'2 by feeding deterrent bioassay,Other,23731643.0,
372,1083211,3,1,,103222017,10205,Unspecified,,,,,Bactericidal activity against Erwinia amylovora 295/93 assessed as growth inhibition in King's B full medium measured at pH 7.2 after overnight incubation by suspension culture assay,Other,23163769.0,
373,1091718,1,1,,103222017,10205,Unspecified,,,,,Antifeedant activity against third instar larvae of Achaea janata in compound treated fresh castor leaves assessed as consumption at 0.1% measured after 6 to 24 hr,Other,19530696.0,
374,1091719,1,1,,103222017,10205,Unspecified,,,,,Antifeedant activity against third-instar larvae of tobacco caterpillar Spodoptera litura in compound treated fresh castor leaves assessed as consumption at 0.1% measured after 6 to 24 hr,Other,19530696.0,
375,1091722,1,1,,103222017,10205,Unspecified,,,,,Toxicity in third instar larvae of Achaea janata assessed as mortality at 4 ug/insect measured after 4 to 28 days by topical bioassay,Other,19530696.0,
376,1091723,1,1,,103222017,10205,Unspecified,,,,,Toxicity in third-instar larvae of tobacco caterpillar Spodoptera litura assessed as mortality at 4 ug/insect measured after 4 to 28 days by topical bioassay,Other,19530696.0,
377,1091724,1,1,,103222017,10205,Unspecified,,,,,"Antifeedant activity against third instar larvae of Achaea janata in compound treated fresh castor leaves assessed as consumption at 28 +/- 2 degC, relative humidity 65 +/- 5 measured after 6 to 24 hr",Other,19530696.0,
378,1091725,1,1,,103222017,10205,Unspecified,,,,,"Antifeedant activity against third-instar larvae of tobacco caterpillar Spodoptera litura in compound treated fresh castor leaves assessed as consumption at 28 +/- 2 degC, relative humidity 65 +/- 5 measured after 6 to 24 hr",Other,19530696.0,
379,1116651,1,2,,103222017,10205,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv grown on Lowenstein-Jensen solid medium assessed as growth inhibition incubated with compound dissolved in DMSO measured after 4 weeks,Other,,
380,1116652,1,2,,103222017,10205,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv grown on Lowenstein-Jensen solid medium assessed as growth inhibition incubated with compound dissolved in water measured after 4 weeks,Other,,
381,1153363,1,1,,103222017,10205,Active,,,,,Cytotoxicity against human MCF7 cells expressing estrogen and progesterone receptor after 72 hrs by MTT assay,Other,24835626.0,
382,1156516,1,1,,103222017,10205,Active,,,43.4,IC50,Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
383,1156517,1,1,,103222017,10205,Active,,,12.2,IC50,Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
384,1156518,1,1,,103222017,10205,Unspecified,,,59.0,IC50,Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
385,1156519,1,1,,103222017,10205,Active,,,34.56,IC50,Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
386,1156520,1,1,,103222017,10205,Unspecified,,,51.12,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
387,1156521,1,1,,103222017,10205,Active,,,17.19,IC50,Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
388,1156522,1,1,,103222017,10205,Active,,,26.2,IC50,Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
389,1157215,1,1,,103222017,10205,Unspecified,,,,IC50,Cytotoxicity against human SW480 cells assessed as cell viability after 24 hrs by MTT assay,Confirmatory,24828199.0,
390,1157216,1,1,,103222017,10205,Unspecified,,,,IC50,Cytotoxicity against human SW480 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,24828199.0,
391,1157217,1,2,,103222017,10205,Unspecified,,,,IC50,Cytotoxicity against human SW620 cells assessed as cell viability after 24 hrs by MTT assay,Confirmatory,24828199.0,
392,1157218,1,2,,103222017,10205,Unspecified,,,,IC50,Cytotoxicity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,24828199.0,
393,1157219,1,1,,103222017,10205,Unspecified,,,,,Inhibition of proto-oncogene protein Wnt/beta-catenin in human SW620 cells assessed as downregulation of TCF/LEF promoter transcriptional activity after 24 hrs by TOPFlash luciferase reporter gene assay,Other,24828199.0,
394,1157220,1,1,,103222017,10205,Inactive,,,,,Inhibition of proto-oncogene protein Wnt/beta-catenin in human SW620 cells assessed as downregulation of mutant TCF/LEF promoter transcriptional activity at 1 to 3 uM after 24 hrs by FOPFlash luciferase reporter gene assay,Other,24828199.0,
395,1157221,1,2,,103222017,10205,Unspecified,,,,,Inhibition of proto-oncogene protein Wnt/beta-catenin in human SW480 cells assessed as downregulation of TCF/LEF promoter transcriptional activity after 24 hrs by TOPFlash luciferase reporter gene assay,Other,24828199.0,
396,1157222,1,2,,103222017,10205,Inactive,,,,,Inhibition of proto-oncogene protein Wnt/beta-catenin in human SW480 cells assessed as downregulation of mutant TCF/LEF promoter transcriptional activity at 1 to 3 uM after 24 hrs by FOPFlash luciferase reporter gene assay,Other,24828199.0,
397,1157223,1,1,,103222017,10205,Active,,,,,Inhibition of proto-oncogene protein Wnt in human SW620 cells assessed as downregulation of beta-catenin protein expression at 6 uM after 24 hrs by Western blot analysis,Other,24828199.0,
398,1157224,1,1,,103222017,10205,Active,,,,,Inhibition of proto-oncogene protein Wnt in human SW620 cells assessed as downregulation of p300 protein expression at 6 uM after 24 hrs by Western blot analysis,Other,24828199.0,
399,1157225,1,1,,103222017,10205,Active,,,,,Inhibition of proto-oncogene protein Wnt in human SW620 cells assessed as downregulation of TCF7L2 protein expression at 6 uM after 24 hrs by Western blot analysis,Other,24828199.0,
400,1157226,1,1,,103222017,10205,Active,,,,,Inhibition of proto-oncogene protein Wnt in human SW620 cells assessed as downregulation of Bcl9l protein expression at 6 uM after 24 hrs by Western blot analysis,Other,24828199.0,
401,1157227,1,1,,103222017,10205,Active,,,,,Inhibition of proto-oncogene protein Wnt in human SW480 cells assessed as downregulation of beta-catenin protein expression at 6 to 10 uM after 24 hrs by Western blot analysis,Other,24828199.0,
402,1157228,1,1,,103222017,10205,Active,,,,,Inhibition of proto-oncogene protein Wnt in human SW480 cells assessed as downregulation of p300 protein expression at 6 to 10 uM after 24 hrs by Western blot analysis,Other,24828199.0,
403,1157229,1,1,,103222017,10205,Active,,,,,Inhibition of proto-oncogene protein Wnt in human SW480 cells assessed as downregulation of TCF7L2 protein expression at 6 to 10 uM after 24 hrs by Western blot analysis,Other,24828199.0,
404,1157230,1,1,,103222017,10205,Active,,,,,Inhibition of proto-oncogene protein Wnt in human SW480 cells assessed as downregulation of Bcl9l protein expression at 6 to 10 uM after 24 hrs by Western blot analysis,Other,24828199.0,
405,1157231,1,1,,103222017,10205,Unspecified,,,,,Inhibition of proto-oncogene protein Wnt/beta-catenin in human SW620 cells assessed as downregulation of c-Myc protein expression at 6 uM after 24 hrs by Western blot analysis relative to control,Other,24828199.0,
406,1157232,1,1,,103222017,10205,Unspecified,,,,,Inhibition of proto-oncogene protein Wnt/beta-catenin in human SW620 cells assessed as downregulation of cyclin D1 protein expression at 6 uM after 24 hrs by Western blot analysis relative to control,Other,24828199.0,
407,1157233,1,1,,103222017,10205,Unspecified,,,,,Inhibition of proto-oncogene protein Wnt/beta-catenin in human SW620 cells assessed as downregulation of vimentin protein expression at 6 uM after 24 hrs by Western blot analysis relative to control,Other,24828199.0,
408,1157234,1,1,,103222017,10205,Active,,,20.0,IC50,Cytotoxicity against human HCT116 cells expressing p53 assessed as cell viability after 24 hrs by MTT assay,Confirmatory,24828199.0,
409,1157235,1,1,,103222017,10205,Active,,,20.0,IC50,Cytotoxicity against p53-deficient human HCT116 cells assessed as cell viability after 24 hrs by MTT assay,Confirmatory,24828199.0,
410,1157236,1,2,,103222017,10205,Active,,,,,Inhibition of proto-oncogene protein Wnt/beta-catenin in human HCT116 cells expressing p53 assessed as downregulation of TCF/LEF promoter transcriptional activity at 5 to 10 uM after 24 hrs by TOPFlash/FOPFlash luciferase reporter gene assay,Other,24828199.0,
411,1157237,1,2,,103222017,10205,Active,,,,,Inhibition of proto-oncogene protein Wnt/beta-catenin in p53-deficient human HCT116 cells assessed as downregulation of TCF/LEF promoter transcriptional activity at 5 to 10 uM after 24 hrs by TOPFlash/FOPFlash luciferase reporter gene assay,Other,24828199.0,
412,1157238,1,1,,103222017,10205,Unspecified,,,,,Inhibition of proto-oncogene protein Wnt in human HCT116 cells expressing p53 assessed as downregulation of beta-catenin protein expression at 10 uM after 24 hrs by Western blot analysis relative to control,Other,24828199.0,
413,1157239,1,1,,103222017,10205,Unspecified,,,,,Inhibition of proto-oncogene protein Wnt in p53-deficient human HCT116 cells assessed as downregulation of beta-catenin protein expression at 10 uM after 24 hrs by Western blot analysis relative to control,Other,24828199.0,
414,1157240,1,1,,103222017,10205,Unspecified,,,,,Upregulation of HBP1 protein expression in human SW620 cells at 6 uM after 24 hrs by Western blot analysis relative to control,Other,24828199.0,
415,1157241,1,1,,103222017,10205,Active,,,,,Upregulation of HBP1 protein expression in human HCT116 cells expressing p53 at 10 uM after 24 hrs by Western blot analysis,Other,24828199.0,
416,1157242,1,1,,103222017,10205,Active,,,,,Upregulation of HBP1 protein expression in p53-deficient human HCT116 cells at 10 uM after 24 hrs by Western blot analysis,Other,24828199.0,
417,1159524,1,1,,26747815,10205,Active,,,8.9125,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
418,1159580,2,1,,268735921,10205,Active,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
419,1160631,1,2,,103222017,10205,Active,223590203.0,2033.0,2.0,IC50,Inhibition of recombinant full length p300 (unknown origin) expressed in baculovirus infected insect Sf21 cells using [3H]acetyl-CoA as substrate,Confirmatory,,
420,1160632,1,2,,103222017,10205,Active,223590203.0,2033.0,2.0,Kd,Binding affinity to p300 (unknown origin) by ITC analysis,Confirmatory,,
421,1166623,1,1,,103222017,10205,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis ATCC 27294 in 7H9 medium after 5 days by Alamar blue assay,Other,25264074.0,
422,1166624,1,1,,103222017,10205,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis ATCC 27294 in high iron condition after 5 days by Alamar blue assay,Other,25264074.0,
423,1166625,1,1,,103222017,10205,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis ATCC 27294 in low iron condition after 5 days by Alamar blue assay,Other,25264074.0,
424,1179567,1,1,,103222017,10205,Active,,,25.5,IC50,Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay,Confirmatory,24913712.0,
425,1179568,1,1,,103222017,10205,Active,,,3.0,IC50,Cytotoxicity against human SAS cells assessed as reduction in cell viability after 48 hrs by MTT assay,Confirmatory,24913712.0,
426,1179569,1,1,,103222017,10205,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus at 100 ug/well after 24 hrs by well diffusion assay,Other,24913712.0,
427,1179570,1,1,,103222017,10205,Inactive,,,,,Antibacterial activity against Pseudomonas aeruginosa MTCC 201 at 100 ug/well after 24 hrs by well diffusion assay,Other,24913712.0,
428,1179571,1,1,,103222017,10205,Unspecified,,,,,Antifungal activity against fluconazole-resistant Candida albicans at 100 ug/well after 24 hrs by well diffusion assay,Other,24913712.0,
429,1179572,1,1,,103222017,10205,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus by NCCLS method,Other,24913712.0,
430,1179573,1,1,,103222017,10205,Unspecified,,,,,Antifungal activity against fluconazole-resistant Candida albicans by NCCLS method,Other,24913712.0,
431,1259310,1,1,,333495234,10205,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
432,1259310,1,1,,333495255,10205,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
433,1259333,1,1,,85789657,10205,Inactive,,,,AC50_uM,"7124-04: Celltiter Glo, Cytotoxicity assay",Other,,
434,1259334,1,1,,85789657,10205,Active,,,12.33,AC50_uM,"7124-02: inhibition of TNFa signaling in B cell lineage, counterscreen",Other,,
435,1259389,1,1,,175607631,10205,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
436,1259389,1,1,,175607890,10205,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
437,1259407,1,1,,363904621,10205,Inactive,,,,,CCRIS mutagenicity studies,Other,,
438,1259409,1,1,,363904621,10205,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
439,1259416,1,2,,375174948,10205,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
440,1259421,1,1,,375174948,10205,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
441,1259423,1,2,,354910993,10205,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
